Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators

US10780092B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Alan Whitehead · Scotch Plains, US
• Olga Ornoski · Teaneck, US
• Subharekha Raghavan · Teaneck, US
• Raphaelle Berger · New York, US
• Joie Garfunkle · Metuchen, US
• Zhiqiang Yang · Westfield, US
• Gang Ji · Beijing, CN
• Falong Jiang · Beijing, CN
• Jianmin Fu · Beijing, CN

Key dates

• Filing date: May 11, 2017
• Grant date: Sep 22, 2020
• Expiry date: May 11, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose.